BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 24640118)

  • 21. Reduced blood platelet sensitivity to aspirin in coronary artery disease: are dyslipidaemia and inflammatory states possible factors predisposing to sub-optimal platelet response to aspirin?
    Markuszewski L; Rosiak M; Golanski J; Rysz J; Spychalska M; Watala C
    Basic Clin Pharmacol Toxicol; 2006 May; 98(5):503-9. PubMed ID: 16635110
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rationale, design and organization of the Second Chinese Cardiac Study (CCS-2): a randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. Second Chinese Cardiac Study (CCS-2) Collaborative Group.
    Second Chinese Cardiac Study (CCS-2) Collaborative Group
    J Cardiovasc Risk; 2000 Dec; 7(6):435-41. PubMed ID: 11189013
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [A 100 years of aspirin: a drug with a future?].
    Sánchez García P
    An R Acad Nac Med (Madr); 1997; 114(1):157-63; discussion 164-7. PubMed ID: 9324911
    [No Abstract]   [Full Text] [Related]  

  • 24. Letter by Cen regarding article, "Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas".
    Cen YY
    Circulation; 2007 Mar; 115(12):e348; author reply e349. PubMed ID: 17389275
    [No Abstract]   [Full Text] [Related]  

  • 25. Aspirin for persons at higher risk for colorectal neoplasia.
    Ritt M
    J Fam Pract; 2004 Aug; 53(8):637-8; author reply 638. PubMed ID: 15298835
    [No Abstract]   [Full Text] [Related]  

  • 26. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
    Bhatt DL; Topol EJ;
    Am Heart J; 2004 Aug; 148(2):263-8. PubMed ID: 15308995
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiplatelet drugs for ischemic stroke prevention.
    Leys D; Balucani C; Cordonnier C
    Cerebrovasc Dis; 2009; 27 Suppl 1():120-5. PubMed ID: 19342841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aspirin for primary prevention of cardiovascular disease?
    Drug Ther Bull; 2009 Nov; 47(11):122-5. PubMed ID: 19887685
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Primary prevention of cardiovascular diseases with acetylsalicylic acid].
    Waltering A; Hemkens L; Florack C
    Dtsch Med Wochenschr; 2005 Dec; 130(49):2847-52. PubMed ID: 16317615
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiinflammatory effects of aspirin in ACS: relevant to its cardiocoronary actions?
    Hohlfeld T; Schrör K
    Thromb Haemost; 2015 Aug; 114(3):469-77. PubMed ID: 26085050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiplatelet therapy in the prevention of ischaemic stroke.
    Verry M; Panak E; Cazenave JP
    Nouv Rev Fr Hematol (1978); 1994 Jun; 36(3):213-28. PubMed ID: 7971242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aspirin as an antithrombotic drug: from the aggregometer to clinical trials.
    de Gaetano G
    Verh K Acad Geneeskd Belg; 1990; 52(6):459-71; discussion 471-3. PubMed ID: 2150736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiplatelet therapy in stroke prevention.
    Apostolakis S; Marín F; Lip GY
    Adv Cardiol; 2012; 47():141-54. PubMed ID: 22906909
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.
    Hennekens CH; Sacks FM; Tonkin A; Jukema JW; Byington RP; Pitt B; Berry DA; Berry SM; Ford NF; Walker AJ; Natarajan K; Sheng-Lin C; Fiedorek FT; Belder R
    Arch Intern Med; 2004 Jan; 164(1):40-4. PubMed ID: 14718320
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Aspirin against cancer].
    Mabro M; de Gramont A
    Rev Med Interne; 2000 Mar; 21 Suppl 1():60s-67s. PubMed ID: 10763206
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding.
    Hsiao FY; Tsai YW; Huang WF; Wen YW; Chen PF; Chang PY; Kuo KN
    Clin Ther; 2009 Sep; 31(9):2038-47. PubMed ID: 19843493
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis.
    Schrör K
    Semin Thromb Hemost; 1997; 23(4):349-56. PubMed ID: 9263351
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aspirin in cardiology--benefits and risks.
    Björklund L; Wallander MA; Johansson S; Lesén E
    Int J Clin Pract; 2009 Mar; 63(3):468-77. PubMed ID: 19222632
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of aspirin in preventing colorectal cancer.
    Burn J; Sheth H
    Br Med Bull; 2016 Sep; 119(1):17-24. PubMed ID: 27543497
    [TBL] [Abstract][Full Text] [Related]  

  • 40. OTC Secondary Prevention of Metastatic Colorectal Cancer Moves Closer to Clinical Reality.
    Chan A
    Oncology (Williston Park); 2015 Jun; 29(6):429-30. PubMed ID: 26126295
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.